{"name":"Precigen","slug":"precigen","ticker":"PGEN","exchange":"NASDAQ","domain":"precigen.com","description":"Precigen, Inc. is an American biotechnology company. Its president and CEO is Helen Sabzevari.","hq":"Germantown, MD","founded":0,"employees":"160","ceo":"Helen Sabzevari","sector":"Synthetic Biology / Cell & Gene Therapy","stockPrice":4.08,"stockChange":-0.04,"stockChangePercent":-0.97,"marketCap":"$1.4B","metrics":{"revenue":45000000,"revenueGrowth":283.6,"grossMargin":0,"rdSpend":41333000,"netIncome":-250642000,"cash":97858000,"dividendYield":0,"peRatio":-18.6,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"PVS-102 patent cliff ($0.0B at risk)","drug":"PVS-102","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"PVS-512 patent cliff ($0.0B at risk)","drug":"PVS-512","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AG019 - High Dose","genericName":"AG019 - High Dose","slug":"ag019-high-dose","indication":"Other","status":"phase_1"},{"name":"AG019 - Low Dose","genericName":"AG019 - Low Dose","slug":"ag019-low-dose","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Zopapogene imadenovec (Zopa)","genericName":"Zopapogene imadenovec (Zopa)","slug":"zopapogene-imadenovec-zopa","indication":"Metastatic melanoma","status":"marketed"}]}],"pipeline":[{"name":"AG019 - High Dose","genericName":"AG019 - High Dose","slug":"ag019-high-dose","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AG019 - Low Dose","genericName":"AG019 - Low Dose","slug":"ag019-low-dose","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Zopapogene imadenovec (Zopa)","genericName":"Zopapogene imadenovec (Zopa)","slug":"zopapogene-imadenovec-zopa","phase":"marketed","mechanism":"Zopapogene imadenovec is an oncolytic adenovirus engineered to express an immunostimulatory transgene that replicates in tumor cells and triggers anti-tumor immune responses.","indications":["Metastatic melanoma"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Precigen Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Precigen reported its financial results for the fourth quarter and full year 2023, with revenue of $13.4 million and a net loss of $34.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Precigen Announces Collaboration with Merck to Develop Gene Therapies for Rare Genetic Disorders","summary":"Precigen announced a collaboration with Merck to develop gene therapies for rare genetic disorders, with an initial focus on the treatment of cystinosis.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Precigen Announces Positive Interim Results from Phase 1/2 Clinical Trial of PVS-102","summary":"Precigen announced positive interim results from a Phase 1/2 clinical trial of PVS-102, a gene therapy candidate for the treatment of cystinosis.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"earnings","source":"simplywall.st","summary":"Precigen (PGEN) Is Up 7.4% After Surging Revenue And Wider 2025 Losses Are Reported – Has The Bull Case Changed? - simplywall.st","headline":"Precigen (PGEN) Is Up 7.4% After Surging Revenue And Wider 2025 Losses Are Reported – Has The Bull Case Changed?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-01","type":"earnings","source":"simplywall.st","summary":"Assessing Precigen (PGEN) Valuation After Wider 2025 Loss And Earnings Release - simplywall.st","headline":"Assessing Precigen (PGEN) Valuation After Wider 2025 Loss And Earnings Release","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-27","type":"earnings","source":"simplywall.st","summary":"Precigen (PGEN) Quarterly Loss Swings Challenge Bullish Growth Narrative After FY 2025 Results - simplywall.st","headline":"Precigen (PGEN) Quarterly Loss Swings Challenge Bullish Growth Narrative After FY 2025 Results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE5XWmlaMFF0aWJTb2Jkb0FJTVludEs3WElWVTZjd2RWd2MtaHBNZDVZY21EOUNzWDhucDdPaDhHTXRqTzhTTTFITXNxZlk2Y3JFXzRfcVF6a29GaFJDdXfSAWNBVV95cUxNcU1OX1VnZWNINldXcmF2WU9tbUt0elFIZ2FsRHV1cjRvSVVWQTJpTXRibzA0dlJVelZyazIwZUZ6ckFvcjdoM3BWLVpoRDhTOUNsS2pqa211MURsYUdDU1ZfRHM?oc=5","date":"2026-03-25","type":"pipeline","source":"Bitget","summary":"Precigen Jumps 28% During the Day: Is This a Biotech Rally or a Risky Move? - Bitget","headline":"Precigen Jumps 28% During the Day: Is This a Biotech Rally or a Risky Move?","sentiment":"neutral"},{"date":"2026-03-25","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-13","type":"pipeline","source":"simplywall.st","summary":"Is Precigen (PGEN) Reflecting Its Recent Surge Despite Steep Short Term Pullback - simplywall.st","headline":"Is Precigen (PGEN) Reflecting Its Recent Surge Despite Steep Short Term Pullback","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxOS0JHUnhScnF5a1ZvZks2SFBZWlhLNVVNY1FxRjF6N1NMb29IRGNrNzZxMjV0QTMwTEs2SWtnTjZXR0FaUFJHNVFQa0lQTmxDMERHQ2NnYlM3ZXFIWnNmelZoaWdrdFFfb19aZ0dueHRYTlRuM0pkRXRTcm8ybW9WUEE1VHFWUDZVWVVwR1NQMjN1QnRHalA2c2ZiUkJIaEZpQjFwM3F4Sk8xaDV2bmpWYkh3NVJPeEZVOURpemxxVk9mRWRKRFRtVzhJS1A3VF96bnBTRm1kdGxkTjN3R2NUTHk3LVd3Rk13dERSVm5IMjZzUEd2QzZHRFNkcnZXNWlaNDJ4b2I3d3M2QkMyVmtKeHFjaGN3WC1yMTBaRThXTkpJUmNuWkozWlpoRXZobVFXZ3RHWHJUZjJIY2ZJOVFVSnJLWlFKUWd3blhxOVU3WkFLWmc?oc=5","date":"2026-01-12","type":"regulatory","source":"PR Newswire","summary":"Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference - PR Newswire","headline":"Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy f","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOMGpGZWgwMzdnTUc3Rl83b3Nidy1wckpHVFhEV1luT0xWNXJhbXBKdThBYmJOcVo5WURMNWlMdjJkb0tUdGlvNzBVb2VaTE5yV0xxWG1vc3JDbmlWUXdfOWZJM1FtaVdvdXlqV2tyMTFqNndQQl9BUG9KcEdrMXlwX2hnU1ZxSkZSSXZCNnpkVUg5dDQ1LS1wc0NVLTNITUhuNkFiMjFZQnAwQW52X1UyTzZJSDdNN1d3LURlQU5mVFIweWlVYTRsUTZR?oc=5","date":"2025-11-13","type":"earnings","source":"PR Newswire","summary":"Precigen Reports Third Quarter 2025 Financial Results and Business Updates - PR Newswire","headline":"Precigen Reports Third Quarter 2025 Financial Results and Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPWnp2NHdLN0VMZk1Ucmg2RThLd1pkT05WTW1JS0cydlVnandkYzZhVG1xOS1jcFUyajVhakhGVUh0LWk5V2tZWW5tc3pJWGIwaHJSUXdLRjdtdXJYeVp5d0p2LWdDbmZEajM2cVhKUXpXeUU3V1Z6dEJ3RzlNNjc3bjhMUXN1cFpjU3U0Y0VGYUprRzZaeFZrTTN1ay1Hbktp?oc=5","date":"2025-08-15","type":"regulatory","source":"Seeking Alpha","summary":"Precigen: This Billion-Dollar Approval Is Still Undervalued (NASDAQ:PGEN) - Seeking Alpha","headline":"Precigen: This Billion-Dollar Approval Is Still Undervalued (NASDAQ:PGEN)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxOb1NLR212RlJKakJ4cEVTTTRHNTR6OFB6cXU2NC0yYzdrV05IZVdCY29NR0xySm9CTVpZd21tYS01T3pHRnN6YXJUMUpKa2JyYktEa3hKQkxKUTI0ZDhUdGc0T01mbV9sb19pM2R4Qnkzc3dzMWtjRXJSeVFNcUJwOGxGZXZCcmZXRTVvamlUWVpHUl9xRk1sd2loQnpoRmI4UFpQNGM4Tk1iMHBiQ0pEVlNaeUxQMjVUS0dzU09JMC1vU0diYUQxU05Zd3BMMVZfNFhGdk1CNTdHMG43ZFE?oc=5","date":"2025-08-15","type":"regulatory","source":"Reuters","summary":"Precigen shares jump after US FDA approves first therapy for rare respiratory disease - Reuters","headline":"Precigen shares jump after US FDA approves first therapy for rare respiratory disease","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxQeGVPcWpDRUZWUGNtaFVLOS1xYTRyMlRjei1wRUpSZ0w0eWNEQTNld2FQcnZjWS0xekJ1QWp3T2RLQU9IUE1fRWpfcHV4dXdIalJSLXhFRFhCOVlObWFvY0tfWC1DMXNfbDMtRlV3RWVFc0tSb0ZXT193X3o0RXYyV3F5UHhWUFJiTUtWZWtqRVRLS2dVUFZvbw?oc=5","date":"2025-08-15","type":"regulatory","source":"The Pharma Letter","summary":"Precigen soars on full FDA approval of Papzimeos - The Pharma Letter","headline":"Precigen soars on full FDA approval of Papzimeos","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxQUGZra3NxMDh4b1gyaUlNMS1fdTA2dWZQQzZKYWZ0ZWRZZF9iM0t6S0FqTWhRTFZhbUxZQU91bmJGYk1EZUNHbVhrZUxMbnBDR19rSHZ0T0xJdlk5aUpRSkhDTkhYNk90d05pZXpkRnNpYWRuRjFjRjh1U2dZdjl6enZsc2ZCMkIxY1pVWm4xOWFiQjN6MVhwTHVB?oc=5","date":"2025-07-07","type":"pipeline","source":"Seeking Alpha","summary":"Precigen: August Is Pivotal For This Biotech Innovator - Seeking Alpha","headline":"Precigen: August Is Pivotal For This Biotech Innovator","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5nNVgtQi1sTG4tejFtOWd6eGNvQ0Y2dXZrOEkyQ2N5cEtFX1E5VnJnZ2xLSDVlcFBvSHhDVEJfbEJNZFZhQWd0Z2VlTnB0U0tZaU1B?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"PGEN Stock Price, News & Analysis - Stock Titan","headline":"PGEN Stock Price, News & Analysis","sentiment":"neutral"}],"patents":[{"drugName":"PVS-102","drugSlug":"cystinosis","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"PVS-512","drugSlug":"rheumatoid-arthritis","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":3,"phaseCounts":{"phase_1":2,"marketed":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Editas Medicine","CRISPR Therapeutics","Intellia Therapeutics"],"therapeuticFocus":["Cancer","Rare Genetic Disorders","Infectious Diseases"],"financials":{"source":"sec_edgar","revenue":17002000,"revenuePeriod":"2019-12-31","revenueHistory":[{"value":17002000,"period":"2019-12-31"},{"value":18299000,"period":"2019-09-30"},{"value":32836000,"period":"2019-06-30"},{"value":22585000,"period":"2019-03-31"},{"value":43185000,"period":"2018-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":41333000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-250642000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":155505000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.08,"previousClose":4.12,"fiftyTwoWeekHigh":5.47,"fiftyTwoWeekLow":1.12,"fiftyTwoWeekRange":"1.12 - 5.47","fiftyDayAverage":4.01,"twoHundredDayAverage":3.51,"beta":1.12,"enterpriseValue":1458618112,"forwardPE":-18.6,"priceToBook":69.24,"priceToSales":149.3,"enterpriseToRevenue":150.62,"enterpriseToEbitda":-14.11,"pegRatio":0,"ebitda":-103401000,"ebitdaMargin":0,"freeCashflow":-53353876,"operatingCashflow":-87831000,"totalDebt":98290000,"debtToEquity":470,"currentRatio":3.09,"returnOnAssets":-44.3,"returnOnEquity":-572,"analystRating":"2.0 - Buy","recommendationKey":"buy","numberOfAnalysts":2,"targetMeanPrice":9.5,"targetHighPrice":10,"targetLowPrice":9,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":13.9,"institutionHeldPercent":73.1,"sharesOutstanding":353928672,"floatShares":168884144,"sharesShort":39788994,"shortRatio":8.31,"shortPercentOfFloat":11.2,"epsTrailing":-1.37,"epsForward":-0.22,"revenuePerShare":0.03,"bookValue":0.06,"officers":[{"age":72,"name":"Mr. Randal J. Kirk J.D.","title":"Executive Chairman"},{"age":63,"name":"Dr. Helen  Sabzevari MPH, Ph.D.","title":"President, CEO & Director"},{"age":63,"name":"Mr. Harry  Thomasian Jr.","title":"Chief Financial Officer"},{"age":44,"name":"Mr. Rutul R. Shah","title":"Chief Operating Officer"},{"age":50,"name":"Mr. Donald P. Lehr J.D., Ph.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":55,"name":"Mr. Phil  Tennant","title":"Chief Commercial Officer"},{"age":null,"name":"Mr. Steven M. Harasym","title":"VP & Head of Investor Relations"},{"age":null,"name":"Mr. Rob  Russell","title":"VP & Head of Human Resources"}],"industry":"Biotechnology","irWebsite":"","website":"https://precigen.com","phone":"301 556 9900"}}